scispace - formally typeset
R

Radu Rapiteanu

Researcher at GlaxoSmithKline

Publications -  10
Citations -  296

Radu Rapiteanu is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: CRISPR & Gene. The author has an hindex of 6, co-authored 9 publications receiving 248 citations. Previous affiliations of Radu Rapiteanu include University of Cambridge & Jacobs University Bremen.

Papers
More filters
Journal ArticleDOI

Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef

TL;DR: This work took a distinct, systems-level, quantitative proteomic approach to gain a comprehensive, unbiased overview of how HIV infection remodels the T cell surface, and defined a unique paradigm of HIV interference with immunometabolism.
Journal ArticleDOI

A non-proteolytic role for ubiquitin in deadenylation of MHC-I mRNA by the RNA-binding E3-ligase MEX-3C

TL;DR: A new role for ubiquitin is established in regulating MHC-I mRNA deadenylation as ubiquitination of CNOT7 by MEX-3C regulates its deadenYLation activity and is required for MHC -I mRNA degradation.
Journal ArticleDOI

Genes on a Wire: The Nucleoid-Associated Protein HU Insulates Transcription Units in Escherichia coli

TL;DR: It is suggested that the nucleoid-associated protein HU is functionally insulating transcription units, most likely by constraining transcription induced DNA supercoiling.
Journal ArticleDOI

A Genetic Screen Identifies a Critical Role for the WDR81‐WDR91 Complex in the Trafficking and Degradation of Tetherin

TL;DR: A forward genetic screen in human haploid KBM7 cells identified WDR81 as a novel gene required for tetherin trafficking and degradation in both the presence and absence of Vpu, and suggests a role for the W DR81‐WDR91 complex in the fusion of endolysosomal compartments and the absence of WDR 81 leads to impaired receptor trafficking and degrade.
Journal ArticleDOI

Single-Step, High-Efficiency CRISPR-Cas9 Genome Editing in Primary Human Disease-Derived Fibroblasts.

TL;DR: A single-step workflow enabling >90% KO generation in primary human lung fibroblasts via CRISPR ribonucleoprotein delivery in the absence of antibiotic selection or clonal expansion is described.